Supporters
Partners
Lupus
Lupus is a chronic, inflammatory autoimmune disorder which affects the skin, joints, kidneys and other organs. The immune system, which normally controls the body’s defenses against infection, is turned against the body’s own cells and tissues, leading to a chronic disease of the affected systems. The cause of the disease is not fully known, but researchers believe it happens following an infection with an organism which looks similar to proteins in the body. The protein is mistakenly targeted instead of the organism. This disease can affect most organs and organ systems in the body, with most people developing arthritis, rashes, kidney problems and blood disorders. The disease affects nine times as many women as men and may occur at any age, but appears most often in people between the ages of ten and 50 years.
| Company | Product | Phase | |
| La Jolla Pharmaceutical Co | Riquent (abetimus sodium) | M | Lupus |
| GlaxoSmithKline | Prestara (prasterone) | III | Lupus |
| Watson Pharmaceuticals Inc | Aslera | III | Systemic Lupus Erythematosus |
| Genentech, Inc. | R1594 | III | Systemic Lupus Erythematosus |
| Genentech Inc | R1594 with Cyclophosphamide, Mycophenolate mofetil and Corticosteroids | III | Systemic Lupus Erythematosus |
| Genentech Inc | Rituxan | III | Systemic Lupus Erythematosus |
| Watson Pharmaceuticals Inc | Trelstar | II | Systemic Lupus Erythematosus |
Transplantation/ Transplant Rejection
Organ and tissue transplants are risky surgeries which aim to replace faulty or diseased organs with new, functioning organs usually donated from family members or organ donors. Patients run the risk, however, of their body not accepting the new organ or tissue, causing an immune system response against the foreign body. This is commonly known as transplant rejection. Systems of rejection tend to include the improper functioning of the organ, general discomfort or illness, pain, swelling and fever. Immunosuppressive drugs are needed to prevent organ rejection because organ and tissue transplantation almost always causes an immune response and could result in destruction of the foreign tissue.
| Company | Product | Phase | |
| XDx | Allo Map Molecular Expression Testing | M | Transplant Rejection |
| Watson Pharmaceuticals Inc | Cyclosporine | M | Transplant Rejection |
| Prometheus Laboratories Inc | Imuran | M | Transplant Rejection |
| PDL BioPharma Inc | Zenapax | M | Transplant Rejection |
| Amgen Inc | Stemgen and Neupogen | M | Transplantation |
| APT Pharmaceuticals Inc | Pulminiq | III | Transplant Rejection |
| Genentech, Inc. | Rituxan | II | Graft Versus Host Disease |
| Facet Biotech Corporation | Daclizumab | II | Transplant Rejection |
| Proteo Inc | Elafin | II | Transplant Rejection |
| Genentech Inc | Raptiva | II | Transplant Rejection |
| XOMA Ltd | Raptiva | II | Transplant Rejection |
| XOMA Ltd | Neuprex | II | Transplantation |
| SuperGen Inc | Partaject Busulfan | II | Transplantation |
| Quark Pharmaceuticals, Inc. | QPI1002 | II | Transplantation |
| Genentech, Inc. | Rituxan with IVIG | II | Transplantation |
